Erdafitinib in locally advanced/metastatic urothelial carcinoma with certain FGFR genetic alterations.
Sign Up to like & getrecommendations! Published in 2022 at "Future oncology"
DOI: 10.2217/fon-2021-1151
Abstract: FGFR inhibitors represent a new and promising therapeutic approach to urothelial cancer (UC). Erdafitinib (Balversa©) was the first FGFR inhibitor approved for the treatment of metastatic UC, showing proper pharmacological activity and a consistent safety… read more here.
Keywords: locally advanced; metastatic urothelial; fgfr inhibitors; urothelial carcinoma ... See more keywords